🔴 Telix Pharmaceuticals is trading 6.27% down today as biotech weakness outweighed positive reaction to results

Telix Pharmaceuticals is trading 6.27% down at A$16.29 as broader biotech weakness outweighed the positive reaction to its August 20, 2026 half-year results.

• Revenue was US$477 million, up 22% year over year, while adjusted EBITDA rose 146% to US$52 million.
• FY2026 revenue guidance of US$950–970 million was reaffirmed; no new company-specific negative catalyst was identified.